Merck’s Rally Reflects Renewed Confidence, but Has the Market Priced in Too Much?

Merck & Co., Inc. (NYSE:MRK) has surged over 38% in 2026 so far, outperforming the broader market. Merck is no longer being valued like a pharmaceutical company whose biggest challenge is looming patent pressure. Yahoo Finance puts the stock at 15.29 times forward earnings, compared with 8.56 times at the end of September 2025. The […]